rs8034802 — LIPC

LIPC rs8034802 — Your HDL Responds to How You Live (If You Carry the A Allele)

Hepatic lipase (HL), encoded by the LIPC gene on chromosome 15, is the enzyme that finishes the job of remodeling lipoprotein particles at the liver surface. After lipoprotein lipase strips triglycerides from VLDL particles in peripheral tissues, the remnants — and the large HDL2 particles that have absorbed cholesterol from arterial walls — arrive at the liver. HL then hydrolyzes their remaining triglycerides and phospholipids, converting HDL2 into the smaller, denser HDL3 particles that are primed for another round of reverse cholesterol transport.

rs8034802 is an intronic variant in LIPC. Unlike the well-characterized promoter variants rs1532085, rs1800588 (-514C>T), and rs2070895 (-250G>A) — which sit in transcription factor binding sites and directly reduce LIPC expression — rs8034802's functional mechanism is not yet fully characterized. What is documented is its association with the same downstream phenotype: higher baseline HDL-C in A allele carriers, alongside a meaningful interaction with lifestyle modification.

The Mechanism

The A allele at rs8034802 is in the same directional pathway as the known LIPC eQTL variants: carriers show elevated total HDL-C, which reflects slowed remodeling of HDL2 into HDL3 rather than increased production of transport-active HDL. When HL activity is reduced, large HDL2 particles accumulate in circulation. This raises the number reported on a standard HDL-C test while the functional capacity of those particles — their efficiency at extracting cholesterol from arterial walls and delivering it to the liver — may not increase proportionally.

The triglyceride side is the other half of the picture. HL also clears triglyceride-rich remnant particles; reduced HL activity allows these to persist longer in circulation, elevating fasting triglycerides. The resulting phenotype — elevated HDL-C alongside elevated triglycerides — is a recognized pattern at the LIPC locus.

The Evidence

The primary evidence for rs8034802 specifically comes from the Look AHEAD study¹¹ Look AHEAD study
Huggins et al. Do genetic modifiers of HDL-C and TG levels also modify their response to a lifestyle intervention in obesity and T2DM? Circ Cardiovasc Genet, 2013, which evaluated 82 SNPs across 31 lipid loci in 3,561 participants with obesity and type 2 diabetes who were randomized to intensive lifestyle intervention (ILI) versus usual diabetes care. Among the GWAS-identified lipid variants studied, rs8034802 was one of only two (alongside CETP rs3764261) associated with both higher baseline HDL-C and a nominally significant HDL-C increase specifically in the ILI group (P=0.013; treatment interaction P=0.046). The variant also showed associations with triglyceride changes during intervention (P<0.05). This makes rs8034802 notable not just as a baseline HDL-C modifier, but as a gene-environment interaction variant where the lifestyle context amplifies the effect.

The broader LIPC literature — including a meta-analysis of 87 studies (101,988 participants)²² meta-analysis of 87 studies (101,988 participants)
Liao et al. The cross-sectional study of hepatic lipase SNPs and plasma lipid levels. Medicine, 2020 — consistently shows that LIPC variants reducing HL activity raise HDL-C while simultaneously elevating triglycerides, LDL, and total cholesterol. A Brazilian cohort study³³ Brazilian cohort study
de Lima et al. LIPC -250A/G variant enhances carotid atherosclerosis. Atherosclerosis, 2020 found that LIPC variants with reduced HL activity paradoxically increased carotid atherosclerosis risk despite higher HDL-C — because the elevated HDL-C comes from accumulation of triglyceride-rich, cholesteryl ester-depleted HDL2 particles with impaired reverse cholesterol transport function.

Evidence for this specific rs8034802 variant is emerging — the Look AHEAD finding is a single large study. The broader LIPC locus has strong evidence, but rs8034802 specifically has not been replicated independently.

Practical Actions

For TT homozygotes (most common in Europeans, ~44% globally), hepatic lipase activity is at the reference level for this variant. Your HDL-C and triglycerides are not influenced by this locus.

For AT heterozygotes (~45% globally), the A allele confers moderately elevated baseline HDL-C. If you have obesity or type 2 diabetes, the Look AHEAD data suggest you may see above-average HDL-C gains from an intensive lifestyle intervention — making it particularly worthwhile to pursue. At the same time, the LIPC pattern of simultaneous HDL-C and triglyceride elevation means fasting triglycerides deserve as much attention as the HDL-C number on your lipid panel.

For AA homozygotes (~11% globally, up to 40% in East Asian populations), the dual elevation of HDL-C and triglycerides is most pronounced. The HDL-C reading may look encouraging on a standard panel, but asking your physician for apolipoprotein A-I (apoA-I) and fasting triglycerides gives a more complete picture of whether your HDL is genuinely protective. The HDL advantage is most preserved when saturated fat intake is limited and omega-3 polyunsaturated fats are emphasized.

Interactions

rs8034802 is located in the same LIPC gene as rs1532085 — the GWAS lead SNP for the LIPC locus (P=9.7×10⁻³⁶ in >100,000 Europeans). If your genetic test reports both variants, rs1532085 has much stronger population-level evidence for hepatic lipase regulation. rs8034802 adds the gene-lifestyle interaction dimension that rs1532085 studies have not specifically characterized.

CETP variants (rs3764261 and rs708272) were co-identified in the Look AHEAD study as the other major lifestyle-modifiable lipid locus. Combined high-HDL genotypes at both CETP and LIPC may amplify the HDL-C response to lifestyle intervention, though the cardiovascular benefit depends on whether the elevated HDL is functionally active (CETP mechanism) or large-particle accumulation (LIPC mechanism).